Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336.SS)
- Previous Close
27.11 - Open
27.11 - Bid 27.34 x --
- Ask 27.35 x --
- Day's Range
26.80 - 27.80 - 52 Week Range
15.22 - 30.67 - Volume
1,832,948 - Avg. Volume
3,939,877 - Market Cap (intraday)
16.863B - Beta (5Y Monthly) 0.41
- PE Ratio (TTM)
23.57 - EPS (TTM)
1.16 - Earnings Date --
- Forward Dividend & Yield 0.08 (0.30%)
- Ex-Dividend Date Sep 27, 2024
- 1y Target Est
--
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of antibody drugs in China. Its products include YISAIPU, a tumor necrosis factor inhibitor type II-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Septin, an initututab for injection; and Xenipax, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation, as well as used in conjunction with conventional immunosuppression regimens to increase the survival rate of transplanted organs and enhance patients' quality of life. The company is also developing products for autoimmune, oncology, ophthalmological, and other diseases. The company was founded in 2002 and is based in Shanghai, China.
www.3s-guojian.comRecent News: 688336.SS
View MorePerformance Overview: 688336.SS
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 688336.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 688336.SS
View MoreValuation Measures
Market Cap
16.86B
Enterprise Value
15.54B
Trailing P/E
23.57
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
13.64
Price/Book (mrq)
2.97
Enterprise Value/Revenue
12.56
Enterprise Value/EBITDA
21.61
Financial Highlights
Profitability and Income Statement
Profit Margin
57.88%
Return on Assets (ttm)
2.30%
Return on Equity (ttm)
13.25%
Revenue (ttm)
1.24B
Net Income Avi to Common (ttm)
716.42M
Diluted EPS (ttm)
1.16
Balance Sheet and Cash Flow
Total Cash (mrq)
1.73B
Total Debt/Equity (mrq)
0.89%
Levered Free Cash Flow (ttm)
-598.58M